Bijou Brigitte modische Accessoires AG
XETRA:BIJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Bijou Brigitte modische Accessoires AG
XETRA:BIJ
|
DE |
|
LVMH Moet Hennessy Louis Vuitton SE
OTC:LVMHF
|
FR |
|
Coca-Cola Femsa SAB de CV
NYSE:KOF
|
MX |
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
CN |
|
Svenska Cellulosa SCA AB
STO:SCA B
|
SE |
|
Betterware de Mexico SAPI de CV
NYSE:BWMX
|
MX |
Bijou Brigitte modische Accessoires AG
Bijou Brigitte modische Accessoires AG engages in manufacture, import, and sale of fashion jewelry, gold and silver jewellery, fashion accessories, and complementary articles. The company is headquartered in Hamburg, Hamburg. The firm manufactures, imports and distributes fashion jewelry, gold and silver jewelry, fashion accessories and complementary products. Its product range includes arm and body jewelry, brooches, chains and hair jewelry as part of its fashion jewelry range; silver jewelry; the designer product series Senso di Donna; gemstone and amber collections; minerals and fossils, and children's jewelry, as well as belts, caps, men's accessories, handbags, scarves, sunglasses and watches, among others. The firm operates through numerous subsidiaries in Europe, as well as in China and the Middle East.
Bijou Brigitte modische Accessoires AG engages in manufacture, import, and sale of fashion jewelry, gold and silver jewellery, fashion accessories, and complementary articles. The company is headquartered in Hamburg, Hamburg. The firm manufactures, imports and distributes fashion jewelry, gold and silver jewelry, fashion accessories and complementary products. Its product range includes arm and body jewelry, brooches, chains and hair jewelry as part of its fashion jewelry range; silver jewelry; the designer product series Senso di Donna; gemstone and amber collections; minerals and fossils, and children's jewelry, as well as belts, caps, men's accessories, handbags, scarves, sunglasses and watches, among others. The firm operates through numerous subsidiaries in Europe, as well as in China and the Middle East.
Revenue Growth: Stryker delivered organic sales growth of 11.9% in the second quarter, with double-digit gains in both MedSurg & Neurotechnology and Orthopaedics & Spine.
EPS & Margins: Adjusted EPS was $2.54, up 13% year-over-year, marking the start of margin recovery. Gross margin improved by 60 basis points versus last year.
Guidance Raised: Management raised full-year organic sales growth guidance to 9.5–10.5% and adjusted EPS to $10.25–$10.45.
Strong Procedural Demand: Surgical backlogs are elevated, supporting strong procedure volumes into 2024. Patient demand remains high, with backlogs longer than normal.
Product Pipeline: Successful limited launch of the 1788 camera, upcoming launches (LIFEPAK 35 defibrillator), and a continued product supercycle are expected to support growth.
International & U.S. Strength: Both U.S. (12%) and International (11.4%) organic sales grew double digits, though China remains a drag due to pricing pressures.
Margins Outlook: Operating margin is improving, with more gains expected in the second half as inflationary and supply chain pressures moderate.
Capital Allocation: Focus remains on debt repayment, but tuck-in M&A continues, and future larger deals are on the radar.
